Ectin Research AB (XSAT:ECTIN B) EBIT : kr-16.89 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB EBIT?

Ectin Research AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was kr-2.29 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-16.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ectin Research AB's annualized ROC % for the quarter that ended in Mar. 2024 was -1,143.79%. Ectin Research AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -87,200.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ectin Research AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -340.15%.

Ectin Research AB EBIT Historical Data

The historical data trend for Ectin Research AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB EBIT Chart

Ectin Research AB Annual Data

Trend

Aug19

Aug20

Dec22

Dec23

EBIT

-0.55

-1.20

-13.32

-17.20

Ectin Research AB Quarterly Data
	Aug19	Aug20	Mar21	Sep21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial								-2.60	-1.33	-2.15	-11.12	-2.29

Competitive Comparison of Ectin Research AB's EBIT

For the Biotechnology subindustry, Ectin Research AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ectin Research AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ectin Research AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ectin Research AB's EV-to-EBIT falls into.

Ectin Research AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.89 Mil.

Ectin Research AB (XSAT:ECTIN B) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ectin Research AB's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-9.156 * ( 1 - 0% )	/	( (0.791	+	0.81)	/ 2 )
=	-9.156	/	0.8005
=	-1,143.79 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.428	-	0.719	-	( 5.836	-	max(0, 1.499	-	6.417	+	5.836	))
=	0.791

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.418	-	0.988	-	( 3.918	-	max(0, 1.788	-	4.408	+	3.918	))
=	0.81

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Ectin Research AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-9.156	/	( ( (0.011 + max(-1.035, 0))	+	(0.01 + max(-1.788, 0)) )	/	2 )
=	-9.156	/	( ( 0.011	+	0.01 )	/	2 )
=	-9.156	/	0.0105
=	-87,200.00 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.464)	-	(0.719	+	0	+	0.78)
=	-1.035

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.988	+	0	+	0.8)
=	-1.788

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ectin Research AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-16.885	/	4.964
	=	-340.15 %

Ectin Research AB EBIT Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ectin Research AB (XSAT:ECTIN B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Pepparedsleden 1, Molndal, SWE, 431 83

Website

https://www.ectinresearch.com

Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines